100本のエピソード
Eagle's Eye View: Your Weekly CV Update From ACC.org American College of Cardiology
-
- 健康／フィットネス
-
-
4.0 • 1件の評価
-
The weekly cardiovascular update from ACC.org Editor-in-Chief Kim Eagle, MD, MACC, covering the hottest cardiovascular topics, from new clinical guidelines to practice-changing research and innovative quality initiatives and tools.
-
Eagle’s Eye View: Pulsed Field Ablation and Pulmonary Vein Isolation, Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives, TAVR or SAVR and Severe Aortic Stenosis
In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives. Finally, Dr. Eagle shares some thoughts on reinterventions after CoreValve/Evolut TAVR or SAVR for treatment of severe aortic stenosis.
Subscribe to Eagle’s Eye View -
Eagle’s Eye View: Cardiac Sarcoidosis, Ischemic Stroke in Women with Atrial Fibrillation, TAVR and Native Aortic Regurgitation
In this week’s View, Dr. Eagle looks at a scientific statement from the American Heart Association on the diagnosis and management of cardiac sarcoidosis. He then examines the temporal trends and clinical implications of ischemic stroke in women with atrial fibrillation. Finally, Dr. Eagle shares some thoughts on transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR).
Subscribe to Eagle’s Eye View -
Eagle’s Eye View: infective Endocarditis After Invasive Dental Procedures, Serious Bleeding in Patients with Atrial Fibrillation Using Diltiazem with Apixaban or Rivaroxaban, Low-Dose Colchicine for Secondary Prevention in Atherosclerosis
In this week’s View, Dr. Eagle looks at a systematic review and meta-analysis of antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures. He then examines the issue of serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban. Finally, Dr. Eagle shares some thoughts on low-dose colchicine for secondary prevention in atherosclerosis.
Subscribe to Eagle’s Eye View
-
Eagle’s Eye View: Introducing ACC24
In this special edition of Eagle’s Eye View, Dr. Eagle introduces you to ACC24 featuring valuable insights into practice-changing updates in care. The topics include late-breaking clinical trials and science focusing on new drugs and device therapies.
Tune into ACC.org’s coverage of ACC.24 to hear from the top experts as they debate, discuss the results of the trials, share visual abstracts and find out how it all fits into your practice. The transformation of care begins at ACC.24.
Subscribe to Eagle’s Eye View -
Eagle’s Eye View: Day 3 -- ACCess Points Daily Wrap Up | ACC 2024
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 3, Monday, April 7 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Monday include TARGET BP I (0:39), DEDICATE-DZHK6 (3:07), and FULL REVASC (6:31). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24.
Subscribe to Eagle’s Eye View -
Eagle’s Eye View: Day 2 -- ACCess Points Daily Wrap Up | ACC 2024
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane review the late-breaking clinical trials from Day 2, Sunday, April 6 at the American College of Cardiology Scientific Sessions 2024 in Atlanta. Trials on Sunday include REDUCE-AMI (0:35), DanGer-Shock (3:28), ULTIMATE-DAPT (6:17) and TACT2 (10:04). For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage Page. Follow the ACC on Social Media and use the hashtag #ACC24.
Subscribe to Eagle’s Eye View